<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04841447</url>
  </required_header>
  <id_info>
    <org_study_id>2018932</org_study_id>
    <nct_id>NCT04841447</nct_id>
  </id_info>
  <brief_title>Membrane Target Detection for Leukemia Treatment</brief_title>
  <official_title>Tumor Cell and DNA Detection in the Blood and Bone Marrow of Patients With Acute Myeloid Leukemia (AML)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Missouri-Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Missouri-Columbia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute myeloid leukemia (AML) accounts for more than 40% of leukemia mortality in the United&#xD;
      States. Each year around ten thousand people die from the disease, most within a few years of&#xD;
      diagnosis. Despite advances in our understanding of the disease, few improvements in the&#xD;
      therapy of AML have been made. Collecting specimen from the blood and bone marrow will&#xD;
      increase understanding of effect of Dipeptidyl Peptidase-4 (DPP-4) Inhibitors on human&#xD;
      AML-SCP to develop individualized therapies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Specific targets and novel strategies to eliminate AML stem cells are required for AML&#xD;
      treatment. Collecting specimen from the blood and bone marrow will increase understanding of&#xD;
      effect of DPP4 inhibitors on human AML-SCP to develop individualized therapies. We will test&#xD;
      the effect of DPP4 inhibitors on human AML-SCP in vitro and in vivo and whether addition of&#xD;
      DPP4 inhibitors can prevent AML relapse once the disease is in the remission stage.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 20, 2020</start_date>
  <completion_date type="Anticipated">March 20, 2026</completion_date>
  <primary_completion_date type="Anticipated">March 20, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>DPP4 inhibitors measured in blood and bone marrow samples will be correlated with patient survival data.</measure>
    <time_frame>5 years</time_frame>
    <description>DPP4 inhibitors measured in blood and bone marrow samples will be used in vitro and in vivo a pre-clinical model.</description>
  </primary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>AML, Adult</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Study sample collection</intervention_name>
    <description>Peripheral blood draws and bone marrow aspiration will be done during clinic visit and hospital stay.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Acute myeloid leukemia patients (participants must be 18 or older).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Acute myeloid leukemia patients, must be 18 or older.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1) Participants with impaired decision-making capacities; 2) Pregnant women or fetuses&#xD;
             ; 3) Children (under 18 in Missouri, also dependent on State law); 4) Non-viable&#xD;
             neonates or neonates of uncertain viability (neonates=newborns); 5) Non-English&#xD;
             speaking subjects; 6) Prisoners.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xunlei Kang, MD.PhD</last_name>
    <phone>5738844524</phone>
    <email>kangxu@health.missouri.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Min Cao, MD</last_name>
    <phone>5738844524</phone>
    <email>caomi@health.missouri.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Missouri</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xunlei Kang, MD.PhD</last_name>
      <phone>573-884-4524</phone>
      <email>kangxu@health.missouri.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 7, 2021</study_first_submitted>
  <study_first_submitted_qc>April 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2021</study_first_posted>
  <last_update_submitted>April 9, 2021</last_update_submitted>
  <last_update_submitted_qc>April 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

